Takeda Pharmaceutical Company Limited (TAK)

Trade TAK now with
2/2/2023 2:30:06 AM Takeda Pharmaceutical 9-month Revenue 2.70 Trln Yen Vs. 3.07 Trln Yen Last Year
1/23/2023 3:04:28 AM Takeda To Acquire Worldwide (ex-China) License Of HUTCHMED's Fruquintinib
1/11/2023 8:41:24 AM Takeda : EXKIVITY Approved In China For Treatment Of Metastatic Non-small Cell Lung Cancer With EGFR
1/9/2023 7:36:08 AM Arrowhead, Takeda Announce Topline Results From SEQUOIA Phase 2 Study Of Fazirsiran
1/5/2023 6:53:44 AM Takeda Announces Favorable Phase 3 Safety And Efficacy Results Of TAK-755 As Enzyme Replacement Therapy For CTTP
12/21/2022 8:11:00 PM Astellas, Eisai, Daiichi Sankyo, Takeda To Collaborate To Reduce Environmental Burden In Field Of Pharma Packaging
12/13/2022 7:07:09 AM Takeda To Buy Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
12/8/2022 6:53:27 AM European Commission Grants Marketing Authorization For Takeda's Dengue Vaccine QDENGA
11/17/2022 8:04:52 AM Takeda : Phase 3 Trial Of ICLUSIG Meets Primary Endpoint In Newly-Diagnosed Ph+ ALL
11/11/2022 2:17:00 AM Takeda: EC Grants Marketing Authorization For LIVTENCITYTM For Cytomegalovirus Infection